

CURRICULUM VITAE

GARY STEVEN GILKESON, M.D.

ADDRESS

VA Address

Rheumatology Division
Room 425A
Strom Thurmond Biomedical Research Building
Ralph H. Johnson VA Medical Center
109 Bee Street
Charleston, SC
Tel: (843) 789-6799

Academic Affiliate Address:

96 Jonathan Lucas Blvd, Ste 912
PO Box 250637
Medical University of South Carolina
Charleston, SC 29425
email: gilkeson@musc.edu

EDUCATION

University	1975	Bachelor of Science summa cum laude Baylor University Waco, Texas
------------	------	----------------------------------------------------------------------------

Medical School	1979	M.D. Southwestern Medical School Dallas, Texas
----------------	------	------------------------------------------------------

POSTDOCTORAL TRAINING

Internship	1979-80	Internal Medicine North Carolina Memorial Hospital Chapel Hill, North Carolina
------------	---------	--------------------------------------------------------------------------------------

Residency	1980-82	Internal Medicine North Carolina Memorial Hospital Chapel Hill, North Carolina
-----------	---------	--------------------------------------------------------------------------------------

Fellowship	1986-89	Rheumatology/Immunology Duke University Medical Center Durham, North Carolina
------------	---------	-------------------------------------------------------------------------------------

MILITARY SERVICE

US Air Force	1982-86	Major, Medical Corp Honorable Discharge 1986
--------------	---------	-------------------------------------------------

ACADEMIC APPOINTMENTS

Staff Internist	1982-86	Department of Internal Medicine Carswell AFB Regional Hospital, Texas
-----------------	---------	--------------------------------------------------------------------------

Clinical Associate	1983-86	Department of Internal Medicine
--------------------	---------	---------------------------------

		Southwestern Medical School Dallas, Texas
Associate in Medicine	1989-90	Duke University Medical Center Durham, North Carolina
Assistant Professor of Medicine	1990-95	Duke University Medical Center
Chief, Rheumatology	1992-96	Durham VA Medical Center
Senior Staff	1994-96	Duke Comprehensive Cancer Center
Assistant Professor of Immunology	1994-96	Duke University Medical Center
Associate Professor of Medicine	1995-96	Duke University Medical Center
Associate Professor of Medicine (tenured)	1996-2000	Medical University of South Carolina
Chief of Rheumatology	1996-2007	Ralph H. Johnson VA Medical Center Charleston, SC
Staff Physician Medical Service	1996-	Ralph H. Johnson VA Medical Center Charleston, SC
Associate Professor of Microbiology/Immunology	1996-	School of Graduate Studies, MUSC
Graduate Faculty	1999	MUSC School of Marine Biosciences,
Professor of Medicine Microbiology/Immunology	2000	Medical University of South Carolina
Vice Chairman for Research	2006-	Department of Medicine, MUSC

LICENSURE

Licensed	1996	State of South Carolina (#18479)
----------	------	----------------------------------

CERTIFICATIONS AND ORGANIZATIONS

Certified	1982	American Board of Internal Medicine
	1988	American Board of Internal Medicine, Subspecialty Rheumatology
Memberships	1987	American College of Rheumatology

- 1987 American Association for the Advancement of Science
- 1990 American Federation of Medical Research
- 1994 American Association of Immunologists
- 1997 Southern Society of Clinical Investigation

AWARDS AND HONORS

Undergraduate

Omicron Delta Kappa
Alpha Chi

Medical School

Alpha Omega Alpha-3rd year
Texas Congressional Merit Scholar
Merck Scholar

Awards

Senior Rheumatology Scholar Award,
American College of Rheumatology, 1989
Henry Christian Award for
Excellence in Research, American
Federation of Clinical Research, 1993
Arthritis Foundation, National Volunteer
Service Award, 2000
Physician of the Year, Ralph H Johnson
VAMC, 2001
Selected to Best Doctors in America, 2002-
2008
Arthritis Foundation Research Hero, 2001
HSS Kirkland Lupus Scholar Award, 2003-
2006
MUSC Outstanding Clinician Award, 2007
Outstanding Mentor Award, Ralph H.
Johnson VAMC, 2007

Advisory Boards

Board of Trustees, Carolina's Chapter
Arthritis Foundation, 1992-1996
Chapter Chairman, 1993-1996

Arthritis Foundation
National Board of Delegates 1993-4
Scientific and Medical Committee 1995-7
Corporate Promotions Task Force 1999-00
Professional Education Committee, 1997-00
Scientific and Medical Committee 2000-2007

Professional Ed Task Force (Chairperson
2001)

National Peer Review Council
Molecular Biology Study Section
Arthritis Foundation, 1993-1995
Chairman, 1994-1995

American College of Rheumatology
Communication and Marketing Committee,
Head, Internet Task Force, 1996-99
Lupus Study Group, 1998-2001
CME Committee, 2000-2003
Committee on Research, 2004-2007
Annual Meeting Program Committee, 2005-
2007
Annual Meeting Abstract Selection
Committee 2003-2005
Chair, Career Development Study Section,
ACR Research and Education Foundation,
2006-2009

NIH General Medicine A1 Study Section
standing member, 1997-2001
Lupus Working Group Task Force, 2005-
2007
Lupus Biomarkers Working Group 2005-

Lupus Foundation of America
Medical Advisory Board, 2001-2004
Chair, Medical and Scientific Committee,
2004-2008
National Board of Directors, 2004-2008
Co-Chair Lupus Flare Definition Committee
2006-

Editorial Boards

MKSAP, 1997 edition, Rheumatology
Associate Editor, Journal of Immunology
1998-2002
Clinical Immunology 2000-2002
Autoimmunity Section Editor 2007-2010
ACR News 1997-2000
Lupus News 1999-2001

Ad hoc Reviewer

Journal of Immunology
Clinical Immunology and Immunopathology
Arthritis and Rheumatism

Journal of Rheumatology
Proceedings of the National Acad Sci, USA
Blood
Journal of Investigative Dermatology
Kidney International
Journal of Clinical Investigation

MUSC/VA service

MUSC Faculty Senate, 2000-2003
MUSC Conflict of Interest Committee,
2000-2003
VA IACUC, 1996-1999, Chair 1999-2003
VA R&D Committee, 1998-2000, 2007-
MUSC University Research Council, Vice
Chair, 2004-2006
MUSC CTSA steering committee, 2006-
MUSC College of Medicine Research
Advisory Council, 2005-
MUSC Provosts Space Committee, 2005-
Department of Medicine Tenure and
Promotion Committee 2002-2005

PUBLICATIONS

- 1) Gilkeson G, Teng R, Stone M, et.al. Detection of myoglobin in human sera by RIA; its utility as an Emergency Room screening procedure for myocardial infarction. *Am. Heart J.* 95: 70-77, 1978.
- 2) Gilkeson G, Delaney R. Effectiveness of sublingual clonidine in patients unable to take oral medications. *Drug Intell. Clin. Pharm.* 21: 262-264, 1987
- 3) Gilkeson G, and Caldwell D. Multiple Acyl CoA Dehydrogenase deficiency presenting as a proximal myopathy. *Arthritis Rheum.* 31: 695-696, 1988.
- 4) Gilkeson G, Polisson R, Sinclair H, Vogler J, Rice J, Caldwell D, Spritzer C, Martinez S. Early detection of carpal erosions in patients with rheumatoid arthritis: a pilot study of Magnetic Resonance Imaging. *J. Rheumatol.* 15: 1361-1366, 1988.
- 5) Gilkeson G, Rice J. Retroperitoneal fibrosis: the forgotten collagen vascular disease. *N.C. Med. J.* 50: 192-194, 1989.
- 6) Shergy W, Gilkeson G, German D. Acute gouty arthritis and intravenous nitroglycerin. *Arch. Intern. Med.* 148: 2505-2506, 1988.
- 7) Gilkeson G, Grudier J, Karounos D, Pisetsky D. Induction of anti-ds DNA antibodies in normal mice by immunization with bacterial DNA. *J. Immunol.* 142:1482-1486, 1989.
- 8) Blum F, Gilkeson G, Greenberg C, Murray J. Migratory superficial thrombophlebitis in association with a lupus anticoagulant. *Int.J.Derm.* 29:190-192, 1990.
- 9) Gilkeson G, Grudier J, Pisetsky D. Response of normal mice to immunization with DNA of various specie origin. *Clin. Immunol. Immunopathol.* 51:362-371, 1989.
- 10) Gilkeson G, Ruiz P, Grudier J, Kurlander R, Pisetsky D. Genetic control of inflammatory arthritis in *lpr* congenic mice. *Clin. Immunol. Immunopathol.* 53:460-474, 1989.
- 11) Pisetsky D, Grudier J, Gilkeson G. The role of immunogenic DNA in the pathogenesis of systemic lupus erythematosus. *Arthritis Rheum.* 33:153-159, 1990.

- 12) Wu D, Gilkeson G, Armitage J, Reich C, Pisetsky D. Selective recognition of DNA antigenic determinants by murine monoclonal antibodies. *Clin. Exp. Immunol.* 82:33-37, 1990.
- 13) Gilkeson G, Pritchard J, Pisetsky D. Cellular requirements for anti-DNA responses in normal mice. *Eur. J. Immunol.* 20:1789-1794, 1990.
- 14) Gilkeson G, Grudier J, Pisetsky D. Specificity of anti-DNA antibodies induced in normal mice by immunization with bacterial DNA. *Clin. Immunol. Immunopath.* 59:288-300, 1991.
- 15) Gilkeson G, Ruiz P, Pritchard A, Pisetsky D. Genetic control of inflammatory arthritis and glomerulonephritis in congenic lpr mice and their F1 hybrids. *J. Autoimmunity.* 4:595-606, 1991.
- 16) Gilkeson G, and Pisetsky D. Effects of structural alterations induced by procainamide on DNA antigenicity. *Life Science Advances: Immunol.* 10:63-68, 1991.
- 17) Messina J, Gilkeson G, Pisetsky D. Stimulation of in vitro lymphocyte proliferation by bacterial DNA. *J. Immunol.* 147:1759-1764, 1991.
- 18) Robertson C, Gilkeson G, Ward M, Pisetsky D. Patterns of heavy and light chain utilization in the antibody response to DNA in normal human subjects and patients with systemic lupus erythematosus. *Clin. Immunol. Immunopath.* 62:25-32, 1992.
- 19) Gilkeson G, Spurney R, Coffman T, Ruiz P, Kurlander R, Pisetsky D. Effect of anti-CD4 treatment on inflammatory arthritis in MRL-lpr/lpr mice. *Clin. Immunol. Immunopath.* 64:166-172, 1992.
- 20) Watson M, Rao J, Gilkeson G, Ruiz P, Eicher E, Pisetsky D, Matsuzawa A, Rochelle J, Seldin M. Genetic analysis of MRL-lpr mice: Relationship of the Fas apoptosis gene to disease manifestations and renal disease modifying loci. *J. Exp. Med.* 176:1645-1656, 1992.
- 21) Pyun E, Pisetsky D, Gilkeson G. The fine specificity of monoclonal anti-DNA antibodies induced in normal mice by immunization with bacterial DNA. *J. Autoimmunity* 1, 11-26, 1993.
- 22) Messina J, Gilkeson G, Pisetsky D. DNA structural requirements for induced lymphocyte proliferation. *Cell. Immunol.* 147:148-157, 1993.
- 23) Bernstein K, Bolshoun D, Gilkeson G, Munns T, Lefkowitz J. Glomerular binding activity in sera detected in a membrane based in vitro assay. *Clin. Exp. Immunol.* 91:449-455, 1993.
- 24) Gilkeson G, Ruiz P, Howell D, Lefkowitz J, Pisetsky D. Induction of immune mediated glomerulonephritis in normal mice immunized with bacterial DNA. *Clin. Immunol. Immunopath.* 68:282-292, 1993.
- 25) Gilkeson G, Bloom D, Pisetsky D, Clarke S. Molecular characterization of anti-DNA antibodies induced in normal mice by immunization with bacterial DNA. *J. Immunol.* 151:1353-1364, 1993.
- 26) Palmer S, Gilkeson G, Pisetsky, D. The effect of sex on the induction of anti-DNA antibodies in normal mice immunized with bacterial DNA. *Lupus* 2: 251-255, 1993.
- 27) Weinberg J, Pisetsky D, Seldin M, Misukonis M, Pippen A, Ruiz P, Wood E, Granger D, Gilkeson, G. The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease. *J. Exp. Med.* 179:651-660, 1994.
- 28) Gilkeson G, Pippen A, Pisetsky D. Induction of crossreactive anti-dsDNA antibodies in preautoimmune NZB/NZW mice by bacterial DNA immunization. *J. Clin. Invest.* 95:1398-1402, 1995.

- 29) Gilkeson G, Bernstein K, Phippen A, Clarke S, Marion T, Pisetsky D, Ruiz P, Lefkowitz J. The effect of somatic mutations within clonal sets of anti-DNA antibodies on specificity and pathogenicity. *Clin. Immunol. Immunopath* 76:59-67, 1995.
- 30) Polisson R, Gilkeson G, Smith E, Pisetsky D, Simon L. A pilot trial of gamma interferon in the treatment of patients with scleroderma; correlation of response with serum IL-2r levels. *J. Rheumatol.* 23:654-664, 1996.
- 31) Gilkeson G, Ruiz P, Alexander A, Phippen A, Lefkowitz J, Pisetsky D. Modulation of renal disease in autoimmune NZB/NZW mice by immunization with bacterial DNA. *J. Exp. Med.* 183:1389-1398, 1996.
- 32) Taylor G, Lee D, Carballo E, Lee D, Lai WS, Thompson M, Patel D, Schankman D, Gilkeson G, Broxmeyer HE, Haynes B, Blackshear P. A pathogenetic role for tumor necrosis factor α in the syndrome of cachexia, arthritis and autoimmunity resulting from tristetraprolin (TTP) deficiency. *Immunity* 4:445-453, 1996.
- 33) Wloch M, Alexander A, Phippen A, Lefkowitz J, Pisetsky D, Gilkeson G. Differences in V κ gene utilization and V H CDR3 sequence among anti-DNA from C3H-lpr mice and lupus mice with nephritis. *Eur. J. Immunol.* 26:2225-2232, 1996.
- 34) Lefkowitz J, Di Valerio R, Norris J, Glick G, Alexander A, Jackson L, Gilkeson G. Molecular characteristics of glomerulotropic autoantibodies in murine lupus. *J. Immunol.* 157:1298-1305, 1996.
- 35) St. Clair E, Wilkinson W, Lang T, Mishikoni M, Sanders L, Pisetsky D, Gilkeson G, Granger D, Weinberg B. Systemic activation of blood mononuclear cells for nitric oxide synthase type 2 expression in rheumatoid arthritis. *J. Exp. Med.* 184:1173-1179, 1996.
- 36) Privalle CT, Keng T, Gilkeson GS, Weinberg JB. The role of nitric oxide and peroxynitrite in the pathogenesis of spontaneous murine autoimmune disease. In: *The biology of nitric oxide.* J. Stamler, SS Gross and S Moncada, Portland Press, London. 20, 1996. Vol 5.
- 37) Korompilias AV, Gilkeson GS, Ortel TL, Seaber AV, Urbaniak JR. Anticardiolipin antibodies and osteonecrosis of the femoral head. *Clin. Orth.* 345:174-180, 1997.
- 38) Wloch MK, Phippen AM, Alexander A, Lefkowitz J, Pisetsky P, Gilkeson G. Molecular characteristics of induced anti-DNA antibodies in pre-autoimmune NZB/NZW mice. *J. Immunol.* 158: 4500-4506, 1997.
- 39) Oates, J, Alexander A, Ruiz P, Phippen A, Gilkeson, G. Effect of late modulation of nitric oxide production on murine lupus. *Clin. Immunol. Immunopath.* 83:86-92, 1997.
- 40) Gilkeson G, Mudgett J, Seldin M, Mishukoni M, Alexander A, Weinberg. Serologic and clinical disease activity in MRL-lpr mice lacking NOS2. *J. Exp. Med.* 186:365-373, 1997.
- 41) Carballo E, Gilkeson G, Blackshear P. Bone marrow transplantation reproduces the tristetraprolin-deficiency syndrome in recombination activating gene-2 (-/-) mice. *J Clin. Invest* 100:986-995, 1997.
- 42) Wloch M, Clarke S, Gilkeson G. Effect of V H CDR3 and light chain use on binding of an anti-DNA antibody from a bacterial DNA immunized mouse. *J Immunol.* 159:6083- 6090, 1997.
- 43) Weinberg JB, Gilkeson GS, Mason RP, Chamultrat W. Nitrosylation of blood hemoglobin and renal non-heme proteins in autoimmune MRL-lpr/lpr mice. *Free Radical Biology in Medicine.* 24:191-196, 1998.
- 44) Watanabe H, Sherris D, Gilkeson G. Effect of soluble CD16 on disease in NZB/NZW mice. *Clin Immunol Immunopath.* 88:91-91, 1998.

- 45) Gilkeson G, Cannon C, Oates J, Reilly C, Petri M. Correlation of a serum measure of nitric oxide production with clinical disease activity measures of lupus. *J Rheum.* 26:318-324, 1999.
- 46) Gilkeson G, Conover J, Pisetsky D, Feagin A, Halpern M, Klinman D. Effect of bacterial DNA on cytokine production by (NZB/NZW) F1 mice. *J Immunol.* 161:3890-3895, 1998
- 47) Reilly C, Oates J, Morrow J, Cook J, Halushka P, Gilkeson G. Modulation of mesangial cell activation in MRL/lpr mice by prostaglandin J2. *J Immunol.* 164:1498-1504, 2000.
- 48) Molano I, Watanabe H, Wloch M, Alexander A, Gilkeson G. Effect of a genetic deficiency of terminal deoxynucleotidyl transferase on autoantibody production in Fas^{lpr} mice. *Clin Immunol.* 94:24-32, 2000.
- 49) Mohan C, Morel L, Yang P, Watanabe H, Gilkeson G, Croker B, Wakeland E. Genetic dissection of lupus pathogenesis: a recipe for nephrophilic autoantibodies. *J Clin Invest.* 103:1685-1695, 1999.
- 50) Oates JC, Christensen EF, Reilly CM, Self SE, Gilkeson GS. Prospective measure of serum 3-nitrotyrosine levels in systemic lupus erythematosus: Correlation with disease activity. *Proc Assoc Amer Phys.* 111(6):611-621, 1999.
- 51) Watanabe H, Circolo A, Holers M, Boackle S, Colten H, Wetsel R, Gilkeson G. Modulation of renal disease in MRL/lpr mice deficient in complement Factor B. *J Immunol.* 164:786-794, 2000.
- 52) Korompilias V, Gilkeson G. Hemorrhage and thrombus formation in early experimental osteonecrosis. *Clinical Orthopaedics and Related Research.* 386:11-18, 2001
- 53) Morel L, Croker B, Blenman K, Huang G, Gilkeson G, Wakeland E. Genetic reconstitution of SLE immunopathology with poly-congenic B6.NZM strains. *Proc Natl Acad Sci. USA* 97:6670-6675, 2000.
- 54) Guyton K, Bond R, Reilly C, Gilkeson G, Halushka P, Cook J. Differential effects of 15-deoxy-Delta(12,14)-prostaglandin J(2) and a peroxisome proliferator-activated receptor gamma agonist on macrophage activation. *J Leuk Bio.* 69:631-638, 2001.
- 55) Reilly CM, Oates JC, Sudian J, Crosby MB, Halushka PV, Gilkeson GS. Prostaglandin J(2) inhibition of mesangial cell iNOS expression. *Clin Immunol.* 98:337-345, 2001
- 56) Privalle CT, Keng T, Gilkeson GS, Weinberg JB. Peroxynitrite formation and decreased catalase activity in autoimmune MRL-lpr/lpr mice. *Molec Med.* 6:779-792, 2000.
- 57) Pandey J, Cooper G, Treadwell E, Gilkeson G, St. Clair E, Dooley MA. Immunoglobulin GM and KM allotypes in systemic lupus erythematosus. *Exp Clin Immunogenetics.* 18:117-122, 2001.
- 58) Sekine H, Reilly C, Molano I, Garnier G, Circolo A, Ruiz P, Holers VM, Boackle SM, Gilkeson GS. Complement Component C3 is Not Required for Full Expression of Immune Complex Glomerulonephritis in MRL/lpr Mice. *J Immunol.* 166:6444-6451, 2001.
- 59) Cooper GS, Treadwell EL, St Clair EW, Dooley MA, Gilkeson GS. Smoking and use of hair treatments in relation to risk of developing systemic lupus erythematosus. *J Rheum.* 28:2653-2656, 2001.
- 60) Reilly C, Farrelly L, Viti D, Redmond S, Hutchison F, Ruiz P, Manning P, Connor J, Gilkeson G. Modulation of renal disease in MRL/lpr mice by pharmacologic inhibition of inducible nitric oxide synthase. *Kidney Int.* 61:839-846, 2002.
- 61) Parks CG, Cooper GS, Nylander-French LA, Sanderson WT, Dement JM, Cohen PL, Dooley MA, Treadwell EL, St Clair E, Gilkeson GS, Hoppin JA, Savitz DA. Occupational exposure

- to crystalline silica and risk of systemic lupus erythematosus: A population-based, case-control study in the Southeastern United States. *Arthritis Rheum.* 46(7):1840-50, 2002.
- 62) Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS. Hormonal and reproductive risk factors for development of systemic lupus erythematosus: Results of a population-based, case-control study. *Arthritis Rheum.* 46(7):1830-9, 2002.
 - 63) Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS. Risk factors for development of systemic lupus erythematosus: allergies, infections, and family history. *J Clin Epidemiol.* 2002, 55(10):982-9.
 - 64) Cooper GS, Parks CG, Treadwell EL, EW St. Clair, Gilkeson GS, Cohen PL, Roubey RAS, Dooley MA. Differences by Race, Sex, and Age in the Clinical and Immunologic Features of Recently-Diagnosed Systemic Lupus Erythematosus Patients in the Southeastern United States. *Lupus*, (in press 2002).
 - 65) Mishra N, Reilly CM, Brown DR, Ruiz P, Gilkeson GS. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. *J Clin Invest.* 2003;111(4):539-552.
 - 66) Fraser PA, Ding WZ, Mohseni M, Treadwell EL, Dooley MA, St Clair EW, Gilkeson GS, Cooper GS. Glutathione s-transferase m null homozygosity and risk of systemic lupus erythematosus associated with sun exposure: a possible gene-environment interaction for autoimmunity. *J Rheumatol.* 2003;30(2):276-82.
 - 67) Peden-Adam MM, Eudaly J, Eudaly E, Dudley A, Zeigler J, Lee A, Robbs J, Gilkeson G, Keil DE. Evaluation of immunotoxicity induced by single or concurrent exposure to N,N-diethyl-m-toluamide (DEET), pyridostigmine bromide (PYR), and JP-8 jet fuel. *Toxicol Ind Health.* 2003 17(5-10):192-209.
 - 68) Thurman JM, Ljubanovic D, Edelstein CL, Gilkeson GS, Holers VM. Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. *J Immunol.* 2003, 170:1517-23.
 - 69) Oates JC, Levesque MC, Hobbs MR, Smith EG, Molano ID, Page GP, Hill BS, Weinberg JB, Cooper GS, Gilkeson GS. Nitric oxide synthase 2 promoter polymorphisms and systemic lupus erythematosus in African-Americans. *J Rheumatol.* 2003, 30(1):60-7.
 - 70) Molano ID, Redmond S, Sekine H, Zhang XK, Reilly C, Hutchison F, Ruiz P, Gilkeson GS. Effect of genetic deficiency of terminal deoxynucleotidyl transferase on autoantibody production and renal disease in MRL/lpr mice. *Clin Immunol.* 107:186-197, 2003.
 - 71) Guyton K, Zingarelli B, Ashton S, Teti G, Tempel G, Reilly C, Gilkeson G, Halushka P, Cook J. Peroxisome proliferator-activated receptor-gamma agonists modulate macrophage activation by gram-negative and gram-positive bacterial stimuli. *Shock.* 2003; 20(1):56-62.
 - 72) Croker BP, Gilkeson G, Morel L. Genetic interactions between susceptibility loci reveal epistatic pathogenic networks in murine lupus. *Genes Immun.* 4(8):575-85, 2003
 - 73) Elliott MK, Jarmi T, Ruiz P, Xu Y, Holers VM, Gilkeson GS. Effects of complement factor D deficiency on the renal disease of MRL/lpr mice. *Kidney Int.* 65(1):129-138, 2004.
 - 74) Sekine H, Watanabe H, Gilkeson GS. Enrichment of anti-glomerular antigen antibody-producing cells in the kidneys of MRL/MpJ-Faslpr mice. *J Immunol.* 15;172(6):3913-21, 2004.
 - 75) Parks CG, Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS, Pandey JP. Systemic lupus erythematosus and genetic variation in the interleukin 1 gene cluster: a population based study in the southeastern United States. *Ann Rheum Dis.* 2004; 63(1):91-4.
 - 76) Parks CG, Hudson LL, Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS, Pandey JP. CTLA-4 gene polymorphisms and systemic lupus erythematosus in a population-

- based study of whites and African-Americans in the southeastern United States. *Lupus*. 13:784-791, 2004.
- 77) Parks CG, Pandey JP, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS, Feghali-Botswick CL, Cooper GS. Genetic polymorphisms in tumor necrosis factor (TNF)-alpha and TNF-beta in a population-based study of systemic lupus erythematosus: associations and interaction with the interleukin-1alpha-889 C/T polymorphism. *Hum Immunol*. 65:622-631, 2004.
 - 78) Zhang XK, Gallant S, Molano I, Moussa OM, Ruiz P, Spyropoulos DD, Watson DK, Gilkeson G. Decreased expression of the Ets family transcription factor Fli-1 markedly prolongs survival and significantly reduces renal disease in MRL/lpr mice. *J Immunol*. 173(10):6481-9, 2004.
 - 79) Reilly CM, Mishra N, Miller JM, Joshi D, Ruiz P, Richon VM, Marks PA, Gilkeson GS. Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. *J Immunol*. 173(6):4171-8, 2004.
 - 80) Douglas G, Reilly C, Dooley MA, Page G, Cooper G, Gilkeson G. Angiotensin-converting enzyme (insertion/deletion) and endothelial nitric oxide synthase polymorphisms in patients with systemic lupus erythematosus. *J Rheumatol*. 31:1756-1762, 2004.
 - 81) Keil D, Dudley A, EuDaly J, Dempsey J, Butterworth L, Gilkeson G, Peden-Adams M. Immunological and hematological effects observed in B6C3F1 mice exposed to JP-8 jet fuel for 14 days. *J Toxicol Environ Health A*. 67:1109-1129, 2004.
 - 82) Peden-Adams MM, Dudley AC, EuDaly JG, Allen CT, Gilkeson GS, Keil DE. Pyridostigmine bromide (PYR) alters immune function in B6C3F1 mice. *Immunopharmacol Immunotoxicol*. 26:1-15, 2004.
 - 83) Thurman JT, Kraus DM, Girardi G, Hourcade D, Kang HJ, Royer PA, Mitchell LM, Giclas PC, Salmon J, Gilkeson G, and Holers VM. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. *Molecular Immunol*. 42:87-97, 2005.
 - 84) Crosby MB, Svenson JL, Zhang J, Nicol CJ, Gonzalez FJ, Gilkeson GS. Peroxisome proliferation-activated receptor (PPAR)gamma is not necessary for synthetic PPARgamma agonist inhibition of inducible nitric-oxide synthase and nitric oxide. *J Pharmacol Exp Ther*. 312: 69-76, 2005.
 - 85) Crosby MB, Svenson J, Gilkeson GS, Nowling TK. A novel PPAR response element in the murine iNOS promoter. *Mol Immunol*. 42:1303-10, 2005
 - 86) Parks CG, Cooper GS, Hudson LL, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS, Pandey JP. Association of Epstein-Barr virus with systemic lupus erythematosus: effect modification by race, age, and cytotoxic T lymphocyte-associated antigen 4 genotype. *Arthritis Rheum* 52:1148-59, 2005
 - 87) Haraldsson MK, dela Paz NG, Kuan JG, Gilkeson GS, Theofilopoulos AN, Kono DH. Autoimmune alterations induced by the New Zealand Black Lbw2 locus in BWF1 mice. *J Immunol* 174:5065-73, 2005.
 - 88) Ginzler, E, Dooley, M, Aranow C., Kim M, Buyon J, Merrill J, Petri M, Gilkeson G. Wallace M. Weisman M, Appel G. Comparison of Mycophenolate Mofetil to Intravenous Cyclophosphamide for Induction Therapy of Severe Active Lupus Nephritis. *NEJM*. 353(21):2219-28, 2005.

- 89) Reilly CM, Olgun S, Goodwin D, Gogal RM Jr, Santo A, Romesburg JW, Ansar Ahmed S, Gilkeson GS. Interferon regulatory factor-1 gene deletion decreases glomerulonephritis in MRL/lpr mice. *Eur J Immunol.* 36:1296-308, 2006.
- 90) Liu J, Karypis G, Hippen KL, Vegoe AL, Ruiz P, Gilkeson GS, Behrens TW. Genomic view of systemic autoimmunity in MRL/lpr mice. *Genes Immun.* 7:156-68, 2006..
- 91) Sekine H, Graham KL, Zhao S, Elliott MK, Ruiz P, Utz PJ, Gilkeson GS. Role of MHC-linked genes in autoantigen selection and renal disease in a murine model of systemic lupus erythematosus. *J Immunol.* 177:7423-34, 2006
- 92) Qing X, Zavadil J, Crosby MB, Hogarth MP, Hahn BH, Mohan C, Gilkeson GS, Bottinger EP, Putterman C. Nephritogenic anti-DNA antibodies regulate gene expression in MRL/lpr mouse glomerular mesangial cells. *Arthritis Rheum.* 54:2198-210, 2006.
- 93) Mikuls TR, Holers VM, Parrish L, Kuhn KA, Conn DL, Gilkeson G, et al. Anti-cyclic citrullinated peptide antibody and rheumatoid factor in African Americans with rheumatoid arthritis. *Arth Rheum.* 54:3057-3059, 2006.
- 94) Peden-Adams MM, Eudaly JG, Heesemann LM, Smythe J, Miller J, Gilkeson GS, Keil DE. Developmental immunotoxicity of TCE. *J Environ Health A Tox Hazard Subst Environ Eng.* 41-249-271, 2006.
- 95) Crosby MB, Zhang J, Nowling TM, Svenson JL, Nicol CJ, Gonzalez FJ, Gilkeson GS. Inflammatory modulation of PPAR gamma expression and activity. *Clin Immunol* 118:276-283, 2006.
- 96) Miwa T, Maldonado M, Zhou L, Yamada K, Gilkeson G, Eisenberg R, Song W. Decay accelerating factor ameliorates systemic autoimmune disease in MRL/lpr mice via both complement dependent and independent mechanisms. *Am J Pathol.* 170:1258-1266, 2007.
- 97) Sekine H Ferreira R, Pann- Hammarstrom Q, Gilkeson, G. Role for Msh5 in the regulation of Ig class switch recombination. *Proc Natl Acad Sci. USA,* 104:7193-7198, 2007.
- 98) Oates JC, Farrelly LW, Hofbauer AF, Wang W, Gilkeson GS. Association of reactive oxygen and nitrogen intermediate and complement levels with apoptosis of peripheral blood mononuclear cells in lupus patients. *Arthritis Rheum.*56(11):3738-47,2007
- 99) Rohrer B, Guo Y, Kunchithapautham K, Gilkeson GS. Eliminating complement factor D reduces photoreceptor susceptibility to light-induced damage. *Invest Ophthalmol Vis Sci.* 48(11):5282-9,2007
- 100) Bouali H, Nietert P, Nowling TM, Pandey J, Dooley MA, Cooper G, Harley J, Kamen DL, Oates J, Gilkeson G. Association of the G-463A myeloperoxidase gene polymorphism with renal disease in African Americans with systemic lupus erythematosus. *J Rheumatol.* 34(10):2028-34, 2007.
- 101) Cooper GS, Treadwell EL, St Clair EW, Gilkeson GS, Dooley MA. Sociodemographic associations with early disease damage in patients with systemic lupus erythematosus. *Arthritis Rheum.*56: 993-9, 2007.
- 102) Alexander JJ, Jacob A, Vezina P, Sekine H, Gilkeson GS, Quigg RJ. Absence of functional alternative complement pathway alleviates lupus cerebritis. *Eur J Immunol.* 37(6):1691-701, 2007.
- 103) Lenderink AM, Liegel K, Ljubanović D, Coleman KE, Gilkeson GS, Holers VM, Thurman JM. The alternative pathway of complement is activated in the glomeruli and tubulointerstitium of mice with adriamycin nephropathy. *Am J Physiol Renal Physiol.* 2007;293(2):F555-64.
- 104) Nowling TK, Fulton JD, Chike-Harris K, Gilkeson GS. Ets factors and a newly identified

- polymorphism regulate Fli1 promoter activity in lymphocytes. *Mol Immunol.* 45(1):1-12, 2008
- 105) Hughes LB, Morrison D, Kelley JM, Padilla MA, Vaughan LK, Westfall AO, Dwivedi H, Mikuls TR, Holers VM, Parrish LA, Alarcón GS, Conn DL, Jonas BL, Callahan LF, Smith EA, Gilkeson GS, Howard G, Moreland LW, Patterson N, Reich D, Bridges SL Jr. The HLA-DRB1 shared epitope is associated with susceptibility to rheumatoid arthritis in African Americans through European genetic admixture. *Arthritis Rheum.* 58(2):349-358, 2008.
- 106) Nath SK, Han S, Kim-Howard X, Kelly JA, Viswanathan P, Gilkeson GS, Chen W, Zhu C, McEver RP, Kimberly RP, Alarcón-Riquelme ME, Vyse TJ, Li QZ, Wakeland EK, Merrill JT, James JA, Kaufman KM, Guthridge JM, Harley JB. A nonsynonymous functional variant in integrin-alpha(M) (encoded by ITGAM) is associated with systemic lupus erythematosus. *Nat Genet.* 40(2):152-4, 2008.
- 107) Mikuls TR, Hughes LB, Westfall AO, Holers VM, Parrish L, van der Heijde D, van Everdingen M, Alarcon GS, Conn DL, Jonas B, Callahan LF, Smith EA, Gilkeson G, Howard G, Moreland LW, Bridges SL Jr. Cigarette smoking, disease severity, and autoantibody expression in African Americans with recent-onset rheumatoid arthritis. *Ann Rheum Dis.* 2008;
- 108) Atkinson C, Qiao F, Song H, Gilkeson GS, Tomlinson S. Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice. *J Immunol.* 180(2):1231-8, 2008.
- 109) Oates JC, Shaftman SR, Self SE, Gilkeson GS. Association of serum nitrate and nitrite levels with longitudinal assessments of disease activity and damage in systemic lupus erythematosus and lupus nephritis. *Arthritis Rheum.* 58(1):263-72, 2008.
- 110) International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN), Harley JB, Alarcón-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Moser KL, Tsao BP, Vyse TJ, Langefeld CD. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXX, KIAA1542 and other loci. *Nat Genet.* 40(2):204-10, 2008.
- 111) Sekine H, Ferreira RC, Pan-Hammarström Q, Hammarström L, Gilkeson GS, Behrens TW. Comment on "Reassessment of the role of mut S homolog 5 in Ig class switch recombination shows lack of involvement in cis- and trans-switching". *J Immunol.* 2009 Apr 15;182(8):4495-6; author reply 496-7.
- 112) Guo L, Deshmukh H, Lu R, Vidal GS, Kelly JA, Kaufman KM, Dominguez N, Klein W, Kim-Howard X, Bruner GR, Scofield RH, Moser KL, Gaffney PM, Dozmorov IM, Gilkeson GS, Wakeland EK, Li QZ, Langefeld CD, Marion MC, Williams AH, Divers J, Alarcón GS, Brown EE, Kimberly RP, Edberg JC, Ramsey-Goldman R, Reveille JD, McGwin G Jr, Vilá LM, Petri MA, Vyse TJ, Merrill JT, James JA, Nath SK, Harley JB, Guthridge JM. Replication of the BANK1 genetic association with systemic lupus erythematosus in a European-derived population. *Genes Immun.* 2009 Apr 2. [Epub ahead of print]
- 113) Namjou B, Sestak AL, Armstrong DL, Zidovetzki R, Kelly JA, Jacob N, Ciobanu V, Kaufman KM, Ojwang JO, Ziegler J, Quismorio FP Jr, Reiff A, Myones BL, Guthridge JM, Nath SK, Bruner GR, Mehriani-Shai R, Silverman E, Klein-Gitelman M, McCurdy D, Wagner-Weiner L, Nocton JJ, Putterman C, Bae SC, Kim YJ, Petri M, Reveille JD, Vyse TJ, Gilkeson GS, Kamen DL, Alarcón-Riquelme ME, Gaffney PM, Moser KL, Merrill JT, Scofield RH, James JA, Langefeld CD, Harley JB, Jacob CO.

- High-density genotyping of STAT4 reveals multiple haplotypic associations with systemic lupus erythematosus in different racial groups. *Arthritis Rheum.* 2009 Apr;60(4):1085-95
- 114) Webb R, Wren JD, Jeffries M, Kelly JA, Kaufman KM, Tang Y, Frank MB, Merrill J, Kimberly RP, Edberg JC, Ramsey-Goldman R, Petri M, Reveille JD, Alarcón GS, Vilá LM, Alarcón-Riquelme ME, James JA, Vyse TJ, Moser KL, Gaffney PM, Gilkeson GS, Harley JB, Sawalha AH. Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to lupus and differential gene expression in patients with systemic lupus erythematosus. *Arthritis Rheum.* 2009 Apr;60(4):1076-84
- 115) Jacob CO, Zhu J, Armstrong DL, Yan M, Han J, Zhou XJ, Thomas JA, Reiff A, Myones BL, Ojwang JO, Kaufman KM, Klein-Gitelman M, McCurdy D, Wagner-Weiner L, Silverman E, Ziegler J, Kelly JA, Merrill JT, Harley JB, Ramsey-Goldman R, Vila LM, Bae SC, Vyse TJ, Gilkeson GS, Gaffney PM, Moser KL, Langefeld CD, Zidovetzki R, Mohan C. Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. *Proc Natl Acad Sci U S A.* 2009 Mar 27. [Epub ahead of print]
- 116) Liu K, Li QZ, Delgado-Vega AM, Abelson AK, Sánchez E, Kelly JA, Li L, Liu Y, Zhou J, Yan M, Ye Q, Liu S, Xie C, Zhou XJ, Chung SA, Pons-Estel B, Witte T, de Ramón E, Bae SC, Barizzzone N, Sebastiani GD, Merrill JT, Gregersen PK, Gilkeson GG, Kimberly RP, Vyse TJ, Kim I, D'Alfonso S, Martin J, Harley JB, Criswell LA; Profile Study Group; Italian Collaborative Group; German Collaborative Group; Spanish Collaborative Group; Argentinian Collaborative Group; SLEGEN Consortium, Wakeland EK, Alarcón-Riquelme ME, Mohan C. Kallikrein genes are associated with lupus and glomerular basement membrane-specific antibody-induced nephritis in mice and humans. *J Clin Invest.* 2009 Apr;119(4):911-23.
- 117) Rohrer B, Long Q, Coughlin B, Wilson RB, Huang Y, Qiao F, Tang PH, Kunchithapautham K, Gilkeson GS, Tomlinson S. A Targeted Inhibitor of the Alternative Complement Pathway Reduces Angiogenesis in a Mouse Model of Age-related Macular Degeneration. *Invest Ophthalmol Vis Sci.* 2009 Mar 5. [Epub ahead of print]
- 118) Keil DE, Peden-Adams MM, Wallace S, Ruiz P, Gilkeson GS. Assessment of trichloroethylene (TCE) exposure in murine strains genetically-prone and non-prone to develop autoimmune disease. *J Environ Sci Health A Tox Hazard Subst Environ Eng.* 2009 Apr;44(5):443-53.
- 119) Keil DE, McGuinn WD, Dudley AC, EuDaly JG, Gilkeson GS, Peden-Adams MM. N,N,-diethyl-m-toluamide (DEET) suppresses humoral immunological function in B6C3F1 mice. *Toxicol Sci.* 2009 Mar;108(1):110-23. Epub 2009 Jan 13.
- 120) Snider AJ, Kawamori T, Bradshaw SG, Orr KA, Gilkeson GS, Hannun YA, Obeid LM. A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis. *FASEB J.* 2009 Jan;23(1):143-52. Epub 2008 Sep 24. PubMed Central PMCID: PMC2626622.
- 121) Njoku C, Self SE, Ruiz P, Hofbauer AF, Gilkeson GS, Oates JC. Inducible nitric oxide synthase inhibitor SD-3651 reduces proteinuria in MRL/lpr mice deficient in the NOS2 gene. *J Investig Med.* 2008 Oct;56(7):911-9.
- 122) Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W, Merrill JT, Weinstein A, McCune WJ, Zhong J, Cai W, Freimuth W; Belimumab Study Group.

- Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. *Arthritis Res Ther*. 2008;10(5):R109. Epub 2008 Sep 11. PubMed Central PMCID: PMC2592791.
- 123) Peden-Adams MM, Eudaly JG, Lee AM, Miller J, Keil DE, Gilkeson GS. Lifetime exposure to trichloroethylene (TCE) does not accelerate autoimmune disease in MRL +/- mice. *J Environ Sci Health A Tox Hazard Subst Environ Eng*. 2008 Oct;43(12):1402-9.
 - 124) Bradshaw S, Zheng WJ, Tsoi LC, Gilkeson G, Zhang XK. A role for Fli-1 in B cell proliferation: implications for SLE pathogenesis. *Clin Immunol*. 2008 Oct;129(1):19-30. Epub 2008 Aug 9. PubMed Central PMCID: PMC2562591.
 - 125) Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Joh T, Linnik MD; LJP 394-90-09 Investigator Consortium. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. *Arthritis Rheum*. 2008 Aug;58(8):2470-80.
 - 126) Reilly CM, Thomas M, Gogal R Jr, Olgun S, Santo A, Sodhi R, Samy ET, Peng SL, Gilkeson GS, Mishra N. The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice. *J Autoimmun*. 2008 Sep;31(2):123-30. Epub 2008 Jul 23.
 - 127) Zhang XK, Moussa O, LaRue A, Bradshaw S, Molano I, Spyropoulos DD, Gilkeson GS, Watson DK. The transcription factor Fli-1 modulates marginal zone and follicular B cell development in mice. *J Immunol*. 2008 Aug 1;181(3):1644-54. PubMed Central PMCID: PMC2504761.
 - 128) Parks CG, Cooper GS, Dooley MA, Park MM, Treadwell EL, Gilkeson GS. Childhood agricultural and adult occupational exposures to organic dusts in a population-based case-control study of systemic lupus erythematosus. *Lupus*. 2008 Aug;17(8):711-9.
 - 129) Svenson JL, Eudaly J, Ruiz P, Korach KS, Gilkeson GS. Impact of estrogen receptor deficiency on disease expression in the NZM2410 lupus prone mouse. *Clin Immunol*. 2008 Aug;128(2):259-68. Epub 2008 May 29.
 - 130) Kamen DL, Barron M, Parker TM, Shaftman SR, Bruner GR, Aberle T, James JA, Scofield RH, Harley JB, Gilkeson GS. Autoantibody prevalence and lupus characteristics in a unique African American population. *Arthritis Rheum*. 2008 May;58(5):1237-47
 - 131) Campbell R Jr, Cooper GS, Gilkeson GS. Two aspects of the clinical and humanistic burden of systemic lupus erythematosus: mortality risk and quality of life early in the course of disease. *Arthritis Rheum*. 2008 Apr 15;59(4):458-64.
 - 132) Anderson E, Nietert PJ, Kamen DL, Gilkeson GS. Ethnic disparities among patients with systemic lupus erythematosus in South Carolina. *J Rheumatol*. 2008 May;35(5):819-25. Epub 2008 Mar 15.
 - 133) Peden-Adams MM, Keller JM, Eudaly JG, Berger J, Gilkeson GS, Keil DE. Suppression of humoral immunity in mice following exposure to perfluorooctane sulfonate. *Toxicol Sci*. 2008 Jul;104(1):144-54. Epub 2008 Mar 20
 - 134) Han S, Guthridge JM, Harley IT, Sestak AL, Kim-Howard X, Kaufman KM, Namjou B, Deshmukh H, Bruner G, Espinoza LR, Gilkeson GS, Harley JB, James JA, Nath SK. Osteopontin and systemic lupus erythematosus association: a probable gene-gender interaction. *PLoS ONE*. 2008 Mar 12;3(3):e0001757. PubMed Central PMCID: PMC2258418.
 - 135) Sawalha AH, Webb R, Han S, Kelly JA, Kaufman KM, Kimberly RP, Alarcón-Riquelme

ME, James JA, Vyse TJ, Gilkeson GS, Choi CB, Scofield RH, Bae SC, Nath SK, Harley JB. Common variants within MECP2 confer risk of systemic lupus erythematosus. *PLoS ONE*. 2008 Mar 5;3(3):e1727. PubMed Central PMCID: PMC2253825.

REVIEWS/CHAPTERS

- 1) Gilkeson G, Caldwell D. Rheumatologic associations with malignancy. *J. Musculoskeletal Med.* 7:64-82, 1990.
- 2) Gilkeson G, Allen N. Retroperitoneal fibrosis, a true connective tissue disease. *Rheum. Dis. Clin. N.A.* 22:23-37, 1996.
- 3) Lefkowitz J, Gilkeson G. Nephritogenic autoantibodies in lupus: Current concepts and continuing controversies. *Arthritis Rheum.* 39:894-903, 1996.
- 4) Pisetsky D, Gilkeson G, St. Clair EW. Systemic lupus erythematosus; Diagnosis and treatment. *Med. Clin. NA.* 81:113-127, 1997.
- 5) Gilkeson G. Inflammatory Mediators. *Primer on the Rheumatic Diseases.* 11th Edition. 1997.
- 6) Gilkeson G, Anderson P. Scientific Basis of Rheumatic Diseases. American College of Physicians Medical Knowledge Self Assessment Program (MKSAP), Rheumatology. 2nd edition, 1997.
- 7) Gilkeson G. Glomerulotrophic autoantibodies in lupus. in *Pathogenesis of Systemic Lupus Erythematosus.* Kammer G, Tsokos G. Eds. Humana Press, pg 448-470, 1999.
- 8) Cooper G, Dooley MA, Treadwell E, St. Clair EW, Gilkeson G. Environmental and hormonal influences on the development of systemic lupus erythematosus. *Arthritis Rheum.* 41:1714-1724, 1998.
- 9) Gilkeson G. Humoral response. in *Molecular Rheumatology.* Tsokos G. Eds. Humana Press 2000 pp59-74.
- 10) Gilkeson G. Nitric oxide and related compounds. In *Arthritis and Associated Conditions; A Textbook in Rheumatology.* Ed Koopman W. Lippincott, Williams and Wilkins 2001, pp236-248
- 11) Oates J, Gilkeson G. Inflammatory Mediators. *Primer on the Rheumatic Diseases.* 12th Edition. 2001 pp 81-88
- 12) Reilly C and Gilkeson G. Use of genetic knockouts to modulate disease expression in a murine model of lupus, MRL/lpr mice. *Immunologic Research* 25:143-153, 2002.
- 13) Oates JC, Gilkeson GS. Mediators of injury in lupus nephritis. *Curr Opin Rheumatol* 14:498-503.2002.
- 14) Oates J, Reilly C, Crosby M, Gilkeson G. PPAR γ agonists; potential use anti-inflammatory agents. *Arthritis Rheum* 4:598-605, 2002.
- 15) Oates JC, Gilkeson GS. Nitric oxide and related compounds. In: Koopman WJ, Moreland LW, editors. *Arthritis and Allied Conditions A Textbook of Rheumatology.* 15th ed. Baltimore: Williams & Wilkins; 2004. p. 541-555.
- 16) Kamen DL, Cooper GS, Bouali H, Shaftman SR, Hollis BW, Gilkeson GS. Vitamin D deficiency in systemic lupus erythematosus. *Autoimmun Rev.* 5:114-7, 2006.
- 17) Nowling TK, Gilkeson GS. Regulation of Fli1 gene expression and lupus. *Autoimmun Rev.* 5:377-82, 2006.
- 18) Oates JC, Gilkeson GS. The biology of nitric oxide and other reactive intermediates in systemic lupus erythematosus. *Clin Immunol.* 118:234-238, 2006
- 19) Bouali H, Gilkeson G. New therapies and preventive strategies to treat and minimize damage in lupus. *Curr Rheumatol Rep.* 7:457-462, 2005.

- 20) Gallant S, Gilkeson G. ETS transcription factors and regulation of immunity. *Arch Immunol Ther Exp.* 54:149-163, 2006.
- 21) Gilkeson GS. Vaccinations in patients with systemic lupus erythematosus- safe but not always effective. *Nat Clin Pract Rheumatol.* 2: 590-591, 2006.
- 22) Nowling T, Gilkeson G. Regulation of Fli1 gene expression and lupus. *Autoimmun Rev.* 5:377-382, 2006.